Polypid Ltd Stock News

New report from PESG Research brand covers PolyPid*, which is tackleing the $10 billion dollar a year surgeical site infections cost with its innovative PLEX technology New report from PESG Research brand covers PolyPid*, which is tackleing the $10 billion dollar a year surgeical site infections cost with its innovative PLEX technology

PETACH TIKVA, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2025 Investor Conference, taking place virtually on Thursday, May 29, 2025.

PolyPid Ltd. (NASDAQ:PYPD ) Q1 2025 Earnings Call May 14, 2025 8:30 AM ET Company Participants Brian Ritchie - Investor Relations Dikla Czaczkes Akselbrad - Chief Executive Officer Jonny Missulawin - Chief Financial Officer Ori Warshavsky - Chief Operating Officer, U.S. Conference Call Participants Roy Buchanan - JMP Securities Chase Knickerbocker - Craig-Hallum Bupalan Pachaiyappan - ROTH Capi...

PolyPid Successfully Completed Enrollment in Phase 3 SHIELD II Trial of D-PLEX100 , with Top-Line Results Anticipated in Current Quarter Company Continues to Advance Regulatory Submission Preparations, Commercial Launch Preparations and Partnering Discussions Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, May 14, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“Po...

PETACH TIKVA, Israel, April 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2025 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 14, 2025. The Company will host a conference c...

PETACH TIKVA, Israel, April 22, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company's management will participate in a fireside chat at The Citizens Life Sciences Conference taking place in New York, NY, from May 7-8, 2025.

PETACH TIKVA, Israel, March 11, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced the successful completion of enrollment in the SHIELD II Phase 3 trial for D-PLEX100 for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery.

PETACH TIKVA, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company's management will present at the 37th Annual ROTH Conference taking place in Dana Point, California, from March 17-18, 2025.